DeCure for Congenital diarrhea 7 with exudative enteropathy
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital diarrhea 7 with exudative enteropathy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital diarrhea 7 with exudative enteropathy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital diarrhea 7 with exudative enteropathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
diacylglycerol O-acyltransferase 1 (DGAT1) — DGAT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VYI · 3.0 Å · ligand [(2~{R})-1-[2-azanylethoxy(oxidanyl)phosphoryl]oxy-3-hexadecanoyloxy-propan-2-yl] (~{Z})-octadec-9-enoate (6OU). Experimental structure, not a prediction.
What the evidence adds up to
Congenital diarrhoea 7 with exudative enteropathy is not named or discussed in any of the three abstracts provided. The 2012 and 2024 reviews cover congenital diarrheal disorders and congenital diarrhoeas and enteropathies as broad categories, but neither mentions a numbered subtype 7 or the term exudative enteropathy. The 2017 case report describes a single infant with microvillus inclusion disease variant caused by a homozygous STX3 mutation, a condition that presents with intractable secretory diarrhoea shortly after birth. That infant had severe vomiting, metabolic acidosis, and mild diarrhoea; electron microscopy of a small intestinal biopsy was consistent with microvillus inclusion disease, and MYO5B mutation was excluded before whole exome sequencing identified the STX3 mutation. No drug treatment, response rate, or survival data are reported in any of the abstracts.
The 2012 review notes that for most congenital diarrheal disorders the disease-gene is known and molecular analysis can contribute to an unequivocal diagnosis, but it provides no specific numbers or outcomes. The 2024 review states that many affected infants present with catastrophic dehydration in the first few days of life, that improved management including intravenous nutrition support has allowed patients to survive beyond childhood, and that many subtypes require prolonged or indefinite parenteral nutrition. It calls for further research to identify new disorders and to develop targeted therapies and a potential long-term cure, but again gives no concrete efficacy data for any drug.
No evidence in these abstracts supports any drug repurposing for congenital diarrhoea 7 with exudative enteropathy. The condition itself is absent from the literature cited. What is missing is any published case series or clinical trial that defines the natural history, genetic basis, or drug response of this specific numbered subtype, as well as funding for basic research to identify the underlying mechanism and patient stratification tools to distinguish it from other congenital enteropathies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Molecular Sciences · 2012 · 74 citations · open access
Congenital Diarrheal Disorders: An Updated Diagnostic Approach
AbstractCongenital diarrheal disorders (CDDs) are a group of inherited enteropathies with a typical onset early in the life. Infants with these disorders have frequently chronic diarrhea of sufficient severity to require parenteral nutrition. For most CDDs the disease-gene is known and molecular analysis may contribute to an unequivocal diagnosis. We review CDDs on the basis of the genetic defect, focusing on the significant contribution of molecular analysis in the complex, multistep diagnostic work-up.
Case Reports in Gastroenterology · 2017 · 20 citations · open access
Microvillus Inclusion Disease Variant in an Infant with Intractable Diarrhea
AbstractMicrovillus inclusion disease (MVID) is a rare autosomal recessive congenital enteropathy characterized by intractable secretory diarrhea. We report a case of MVID variant with a homozygous gene mutation in syntaxin 3 <i>(STX3)</i>. The patient is a male Saudi infant who presented shortly after birth with severe vomiting, metabolic acidosis, and mild diarrhea. Electron microscopy study for small intestinal biopsy was consistent with MVID. MYO5B gene mutation was excluded; subsequently, whole exome sequencing (WES) was performed, which revealed homozygous gene mutation in <i>STX3</i>. Using WES in clinical environment can be a useful tool for diagnosing difficult and rare inherited congenital enteropathies.
Extremely rare cause of congenital diarrhea: Enteric anendocrinosis
AbstractCongenital diarrheal disorders consist of a variety of chronic enteropathies. There are approximately 30 different diseases that can be classified into four groups according to the mechanisms involved in pathogenesis: (i) absorption and transport of nutrients and electrolytes; (ii) enterocyte differentiation and polarization; (iii) enteroendocrine cell differentiation; and (iv) modulation of the intestinal immune response. Affected patients often present with life-threatening diarrhea, in the first few weeks of life. A new disorder, enteric anendocrinosis, which is characterized by severe malabsorptive diarrhea and a lack of intestinal enteroendocrine cells has recently been described in six patients with recessively inherited mutations in the Neurogenin-3 gene. In this report we describe a seventh case with a review of the literature.
AbstractCongenital diarrhoeas and enteropathies (CODE) are a heterogeneous group of disorders. Many affected infants present with catastrophic dehydration in the first few days of life, although the clinical phenotype is variable. Advances in the understanding of underlying pathomechanisms and genetic testing, as well as improved management, in particular intravenous nutrition support, have allowed affected patients to survive well beyond childhood. Awareness and understanding of these rare diseases are hence needed, both amongst paediatricians and adult physicians. In this review, we discuss the different groups of disorders based on a review of the current literature and provide a diagnostic and therapeutic approach. Many of the subtypes of CODE result in the need for prolonged or indefinite parenteral nutrition. Further research is needed to identify new CODE to improve the recognition and management of these children, which can assist in developing new targeted therapies and potentially a long-term cure.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
